BamSEC and AlphaSense Join Forces
Learn More

Medicines Co

Formerly NASDAQ: MDCO
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q ~10 pages The Medicines Company 8 Sylvan Way Parsippany, Nj 07054 USA
12/34/56
EX-10.2
from 8-K 7 pages Mark Timney by Hand/Email December 10, 2018 Dear Mark, as an Incentive to Induce You to Join the Medicines Company (The “Company”) as Its Chief Executive Officer, the Company Agrees, on the Terms and Subject to the Conditions Set Forth in This Letter (This “Agreement”), as Follows: 1. as Used Herein, the Following Terms Shall Have the Following Meanings
12/34/56
EX-10.1
from 8-K 8 pages Employment Agreement
12/34/56
EX-10.3
from 10-Q 6 pages Amendment
12/34/56
EX-10.2
from 10-Q 10 pages The Medicines Company Form of Non-Statutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan
12/34/56
EX-10.29
from 10-K 2 pages 8 Sylvan Way Parsippany, Nj 07054 Ex - 10.29 November 14, 2017
12/34/56
EX-10.9
from 10-K 4 pages Amendment
12/34/56
EX-10.1
from 10-Q 4 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Amendment No. 2 to the Supply and Distribution Agreement
12/34/56
EX-10.16
from 10-K 4 pages Background
12/34/56
EX-10.1
from 10-Q 47 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Other Transaction Agreement (Ota) Between the Medicines Company 8 Sylvan Way Parsippany, New Jersey, 07054 and the United States of America Department of Health and Human Services Assistant Secretary for Preparedness and Response 330 Independence Avenue, Sw G640 Washington, DC 20201 (The “Parties”) Concerning
12/34/56
EX-10.6
from 8-K 28 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Bank of America, N.A. (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.5
from 8-K 28 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Jpmorgan Chase Bank, National Association, London Branch (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.4
from 8-K 28 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Goldman, Sachs & Co. (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.3
from 8-K 27 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Bank of America, N.A. (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.2
from 8-K 27 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Jpmorgan Chase Bank, National Association, London Branch (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.1
from 8-K 27 pages The Purpose of This Communication (This “Confirmation”) Is to Set Forth the Terms and Conditions of the Above-Referenced Transaction Entered Into on the Trade Date Specified Below (The “Transaction”) Between Goldman, Sachs & Co. (“Dealer”) and the Medicines Company (“Counterparty”). This Communication Constitutes a “Confirmation” as Referred to in the Agreement Specified Below
12/34/56
EX-10.3
from 8-K 8 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 8-K 1 page Amendment No. 1 to the Medicines Company 2010 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 2 pages Amendment No. 3 to the Medicines Company 2013 Stock Incentive Plan
12/34/56
EX-10.1
from 10-Q 8 pages Amendment
12/34/56